Literature DB >> 12020548

Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls.

Stuart J Pocock1, Tim C Clayton, Douglas G Altman.   

Abstract

Survival plots of time-to-event data are a key component for reporting results of many clinical trials (and cohort studies). However, mistakes and distortions often arise in the display and interpretation of survival plots. This article aims to highlight such pitfalls and provide recommendations for future practice. Findings are illustrated by topical examples and also based on a survey of recent clinical trial publications in four major journals. Specific issues are: should plots go up or down (we recommend up), how far in time to extend the plot, showing the extent of follow-up, displaying statistical uncertainty by including SEs or CIS, and exercising caution when interpreting the shape of plots and the time-pattern of treatment difference.

Entities:  

Mesh:

Year:  2002        PMID: 12020548     DOI: 10.1016/S0140-6736(02)08594-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  102 in total

1.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba; Gary Dahl; Raul C Ribeiro; W Paul Bowman; Jeffrey Taub; Stanley Pounds; Bassem I Razzouk; Norman J Lacayo; Xueyuan Cao; Soheil Meshinchi; Barbara Degar; Gladstone Airewele; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; James R Downing; Wing Leung; Ching-Hon Pui; Dario Campana
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

2.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

3.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  BMC Med       Date:  2012-05-29       Impact factor: 8.775

4.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

5.  Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.

Authors:  Ralf Metzger; Ute Warnecke-Eberz; Hakan Alakus; Fabian Kütting; Jan Brabender; Daniel Vallböhmer; Peter P Grimminger; Stefan P Mönig; Uta Drebber; Arnulf H Hölscher; Elfriede Bollschweiler
Journal:  J Gastrointest Surg       Date:  2011-09-29       Impact factor: 3.452

6.  The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

Authors:  Derek C Angus; Pierre-Francois Laterre; Jeff Helterbrand; E Wesley Ely; Daniel E Ball; Rekha Garg; Lisa A Weissfeld; Gordon R Bernard
Journal:  Crit Care Med       Date:  2004-11       Impact factor: 7.598

7.  Prognosis of early esophageal cancer: differences between squamous cell carcinoma and adenocarcinoma.

Authors:  Elfriede Bollschweiler; Arnulf H Hölscher
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

8.  Workers' beliefs and expectations affect return to work over 12 months.

Authors:  Martijn W Heymans; Henrica C W de Vet; Dirk L Knol; Paulien M Bongers; Bart W Koes; Willem van Mechelen
Journal:  J Occup Rehabil       Date:  2006-12

9.  Risk of chipping or facings failure of metal ceramic fixed partial prostheses--a retrospective data record analysis.

Authors:  Michael Behr; Christina Winklhofer; Maria Schreier; Florian Zeman; Carola Kobeck; Isabel Bräuer; Martin Rosentritt
Journal:  Clin Oral Investig       Date:  2011-02-02       Impact factor: 3.573

10.  Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study.

Authors:  D Aletaha; T Stamm; T Kapral; G Eberl; J Grisar; K P Machold; J S Smolen
Journal:  Ann Rheum Dis       Date:  2003-10       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.